Short Interest in Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Grows By 797.8%

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 34,223 shares, an increase of 797.8% from the August 15th total of 3,812 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 114,861 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analyst Weigh In

A number of equities analysts have commented on SGIOY shares. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

OTCMKTS SGIOY traded up $0.02 on Thursday, reaching $9.04. The company had a trading volume of 202,000 shares, compared to its average volume of 81,849. The stock has a market capitalization of $15.39 billion, a PE ratio of 9.04, a price-to-earnings-growth ratio of 3.23 and a beta of 0.08. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $7.65 and a 12 month high of $12.00. The company has a quick ratio of 1.46, a current ratio of 1.14 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average price is $8.96 and its 200 day moving average price is $9.60.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its earnings results on Monday, August 3rd. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%.The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million. As a group, equities analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.